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A B S T R A C T
Background
Guidelines and clinical practice for the prevention of complications associated with central venous catheters (CVC) around the world
vary greatly. Most institutions recommend the use of heparin to prevent occlusion, however there is debate regarding the need for
heparin and evidence to suggest 0.9% sodium chloride (normal saline) may be as effective. The use of heparin is not without risk, may
be unnecessary and is also associated with increased cost.
Objectives
To assess the clinical effects (benefits and harms) of intermittent flushing of heparin versus normal saline to prevent occlusion in long
term central venous catheters in infants and children.
Search methods
The Cochrane Vascular Trials Search Co-ordinator searched the Specialised Register (last searched April 2015) and the Cochrane
Register of Studies (Issue 3, 2015). We also searched the reference lists of retrieved trials.
Selection criteria
Randomised controlled trials that compared the efficacy of normal saline with heparin to prevent occlusion of long term CVCs in
infants and children aged up to 18 years of age were included. We excluded temporary CVCs and peripherally inserted central catheters
(PICC).
Data collection and analysis
Two review authors independently assessed trial inclusion criteria, trial quality and extracted data. Rate ratios were calculated for
two outcome measures - occlusion of the CVC and central line-associated blood stream infection. Other outcome measures included
duration of catheter placement, inability to withdraw blood from the catheter, use of urokinase or recombinant tissue plasminogen,
incidence of removal or re-insertion of the catheter, or both, and other CVC-related complications such as dislocation of CVCs, other
CVC site infections and thrombosis.
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Main results
Three trials with a total of 245 participants were included in this review. The three trials directly compared the use of normal saline and
heparin, however, between studies, all used different protocols for the standard and experimental arms with different concentrations of
heparin and different frequency of flushes reported. In addition, not all studies reported on all outcomes. The quality of the evidence
ranged from low to very low because there was no blinding, heterogeneity and inconsistency between studies was high and the confidence
intervals were wide. CVC occlusion was assessed in all three trials (243 participants). We were able to pool the results of two trials for
the outcomes of CVC occlusion and CVC-associated blood stream infection. The estimated rate ratio for CVC occlusion per 1000
catheter days between the normal saline and heparin group was 0.75 (95% CI 0.10 to 5.51, two studies, 229 participants, very low
quality evidence). The estimated rate ratio for CVC-associated blood stream infection was 1.48 (95% CI 0.24 to 9.37, two studies,
231 participants; low quality evidence). The duration of catheter placement was reported to be similar between the two study arms, in
one study (203 participants).
Authors’ conclusions
The review found that there was not enough evidence to determine the effects of intermittent flushing of heparin versus normal saline
to prevent occlusion in long term central venous catheters in infants and children. Ultimately, if this evidence were available, the
development of evidenced-based clinical practice guidelines and consistency of practice would be facilitated.
P L A I N L A N G U A G E S U M M A R Y
Replacing heparin with saline to prevent complications in long term central venous catheters in children
Background
A central venous catheter (CVC) is a long, thin, flexible tube which is inserted into a large central vein. This enables access to the
blood stream for people with serious medical conditions to receive medications and fluids, as well as the collection of blood specimens.
Long term central venous catheters are used to access the blood system in children with complex medical conditions like cancer. To
stop the catheter from becoming blocked it is usual to use heparin, a drug that prevents clots forming, to flush the catheter. However,
some studies have shown that heparin is not necessary, and that normal saline (a sterile salt water solution) can be safely used instead.
Heparin may be associated with complications, such as bleeding and infection, along with higher costs for health care providers. While
the complications such as infections and occlusions are uncommon, practices vary around the world and there are many inconsistencies
regarding the best flush solution to use to prevent complications in long term catheters.
Study characteristics and key results
This review included randomised controlled trials, (clinical studies where people were randomly assigned into one of two or more
treatment groups), that compared the use of saline and heparin to prevent blockage, and other complications related to long term
catheters. The evidence is current to April 2015. Two review authors independently reviewed the studies. Three studies with a total of
245 participants were included in the review. The three trials directly compared the use of saline and heparin, however, between studies,
all were very different in the way they compared saline and heparin, with different concentrations of heparin and different frequency of
flushes reported. We were able to combine the results of two studies; the analysis showed imprecise results for the blocking of catheters
and blood stream infections between normal saline and heparin. One study reported the duration of catheter placement to be similar
between the two study arms.
Quality of the evidence
The overall quality of the evidence ranged from low to very low. There was high risk of bias for blinding, there were differences between
the studies methods and interventions, inconsistent results between the studies, and not all studies reported all outcomes of interest.
We found there was not enough evidence to determine which solution, heparin or saline, is more effective for reducing complications.
Further research is required and is likely to have an important impact in this area.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Heparin versus normal saline flushing for prevention of occlusion in long term central venous catheters in infants and children
Patient or population: Infants and children with a long term central venous catheter
Settings: Tertiary hospitals
Intervention: Heparin flush
Control: normal saline flush
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control: normal saline
flush
Comparison: Heparin
flush
CVC occlusion rate per
1000 catheter days
Ability to infuse solution
through CVC
Follow-up: 3029 to 115,
991 at-risk days
Study population Rate ratio 0.75
(0.10 to 5.51)
229
(2 studies)
⊕©©©
very low2,3,4
551 per 1000 507 per 1000
(99 to 1000)
Moderate
549 per 1000 505 per 1000
(99 to 1000)1
CVC-associated blood
stream infection rate per
1000 catheter days
Incidence of positive
blood culture
Follow-up: 3029 to 115,
991 at-risk days
Study population Rate ratio 1.48
(0.24 to 9.37)
231
(2 studies)
⊕⊕©©
low2,4,5,6
93 per 1000 209 per 1000
(103 to 425)
Moderate
98 per 1000 220 per 1000
(109 to 447)1
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; CVC: Central venous catheter
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Moderate risk group was assumed based on the moderate risk for CVC occlusion and CVC-associated blood stream infection in the
Cesaro 2009 study
2 No blinding in either study. Peformance and detection bias is high in both studies
3 Heterogeneity and inconsistency between studies is high
4 Confidence intervals were wide and included the null hypothesis
5 Results could be attributed to other factors associated with the use of heparin
6 The outcomes could also be attributed to the use of positive pressure cap in the Cesaro 2009 study
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B A C K G R O U N D
Description of the condition
A central venous catheter (CVC) is a long, thin, flexible tube which
is inserted into a large central vein, with the tip of the catheter
ideally placed within the superior vena cava (Schuster 2000). This
enables the administration of medications and fluids, as well as the
collection of blood specimens to avoid unnecessary venipunctures.
CVCs are commonly known as ’central lines’ or by their brand
name including Broviac, Hickman, and Port-a-Cath. The use of
long term CVCs for the management of chronic medical condi-
tions in infants and children has greatly improved the quality and
safety of care provision. Long term CVCs are typically inserted
when the administration of intravenous medication or nutritional
support is required over a considerable time period. Hypertonic
medications such as vesicant chemotherapy drugs, certain antibi-
otics, other supportive drugs and parenteral nutrition, are not able
to be safely administered through peripheral venous catheters. For
children with cancer and other chronic medical conditions who
require suchmedications, this safety issue is overcome by the inser-
tion of a CVC which commonly remains in place for the duration
of treatment (Gonzalez 2012). There are three types of long term
CVCs: tunnelled catheters; totally implanted catheters; and pe-
ripherally inserted central catheters (PICC). A tunnelled CVC is
surgically inserted under the skin, with the catheter lumen(s) typ-
ically exiting from the chest or neck. A totally implanted catheter
is also surgically inserted, but is placed entirely under the skin and
commonly referred to as a ’port’. The port reservoir is accessed
with a needle through the skin. A PICC line is inserted into a
central vein through the arm and thus is a narrower catheter.
Adverse events associated with CVCs may cause complications
in up to 46% of children (Athale 2012). Adverse events in the
scope of this review include mechanical failure, catheter fracture,
infections and thrombotic complications, all of which can affect
patient morbidity and mortality (Baskin 2009; Fratino 2005;
Stocco 2012; Wong 2012). Mechanical failure is often attributed
to catheter occlusion. Over time, it is common for a fibrin sheath
to develop at the tip of the catheter. The fibrin sheath may prevent
aspiration of blood from the catheter and cause resistance when
infusing fluids. An intraluminal clot can also occur, which can
totally occlude the catheter.Occlusion can result in the need for the
catheter to be removed (and replaced), interrupting and delaying
treatment of the underlying disease (Shah 2007). Occlusions of
CVCs are estimated to occur in 14% to 36%of patients within one
to two years of catheter insertion, (Fratino 2005) or at an incidence
rate of 1.35 per 1000 catheter days (95% confidence interval (CI)
1.1 to 1.63) (Revel-Vilk 2010). Incidence rates of central line-
associated blood stream infection differ depending upon the type
of catheter, with rates reported between 1.40 per 1000 catheter
days (95%CI 1.06 to 1.82) and 0.46 per 1000 catheter days (95%
CI 0.29 to 0.69). Thrombotic complications are the rarest adverse
events reported in children, with a lower incidence rate of 0.08
per 1000 catheter days (95% CI 0.04 to 0.16) (Fratino 2005).
Description of the intervention
A flush refers to solution of 0.9% sodium chloride being injected
to clear the catheter of blood or fibrin build-up. This is commonly
used when the catheter is accessed, between administration of
medications, or before and after collection of blood specimens.
A positive pressure lock is used when the catheter will not be
accessed for a period of time, and refers to the technique used
to ensure blood does not flow back into the catheter after it is
flushed, which may otherwise clot and cause occlusion. Tunnelled
CVCs and PICC lines are typically flushed and locked weekly,
while implanted ports are flushed and locked every 4 to 6 weeks.
A typical lock solution for tunnelled catheters in children is to use
between 1ml to 3ml (depending on the volume of the catheter) of
10 units/ml of heparin for a 24-hour to 7-day lock. For implanted
ports, 5 mL of 100 units/mL is typically used as a lock solution for
a 30-day lock (Davis 2013). However, there is debate regarding
the effectiveness of heparin to prevent occlusion over such time
periods, given its short half-life (Young 2008). The evidence to
support the use of heparin to prevent occlusion in adult CVCs is
inconclusive and there is growing evidence to support the use of
0.9% sodium chloride (normal saline) to lock CVCs, particularly
in the paediatric population (Bertoglio 2012; Lee 2005).
How the intervention might work
Heparin is used to prevent occlusion because of its anti-coagu-
lant properties which are believed to prevent thrombus forming in
the catheter. Alternatively normal saline, when used with pulsatile
(push-pause rather than continuous) flushing techniques and a
positive pressure lock or positive displacement device, may be as
effective in preventing thrombus formation in catheters - elimi-
nating the need for heparin to be used.
Why it is important to do this review
Cathter maintenance practices vary among institutions because
of the lack of evidence regarding best practice to prevent occlu-
sion of CVCs. Variations include the quantity of flush and lock
solutions, the proportional volume of heparin lock solution, and
the frequency of flushes and locks. The use of heparin is not risk
free and in certain instances may actually cause harm, including
infection (Shanks 2005) and heparin-induced thrombocytopenia
(HIT) (Barclay 2012). The mechanism of haemostasis in children
is different when compared to adults, particularly in infants and
very young children, and the evidence suggest algorithms used in
adults are unlikely to be valid in children (Monagle 2010). Addi-
tionally, treatments for diseases such as cancer involve the use of
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medications which can affect coagulation. In the absence of spe-
cific data related to pediatrics, using evidence based on adults may
be inappropriate and there is a need for paediatric-specific studies
(Monagle 2010). For these reasons the use of heparin to prevent
CVC occlusion should be judicious and evidence-based. While
the risks of adverse effects from the use of heparin may be regarded
as less than the potential occlusion of a catheter and subsequent
replacement, it is important to ensure interventions are based on
evidence.
In the adult population, there have been several trials (Goossens
2013; Schallom 2012; Schilling 2006), a systematic review
(Mitchell 2009), and a Cochrane Review of the use of heparin
versus normal saline to prevent occlusions in CVCs (Lopez-Briz
2014). As evidence from adult studies is not directly transferable
to paediatrics, a systematic review focused on infants and children
is required. A review published in 2014 (Conway 2014), that did
relate specifically to paediatrics, did not identify all relevant stud-
ies and made recommendations based on the current practice of
several institutions. These recommendations were not evidence-
based, and are contrary to the practice of many other institutions.
Therefore, it is important to systematically appraise the evidence
for the use of heparin compared with normal saline to prevent
occlusion of central venous catheters.
O B J E C T I V E S
To assess the clinical effects (benefits and harms) of intermittent
flushing of heparin versus normal saline to prevent occlusion in
long term central venous catheters in infants and children.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials that compared the efficacy of hep-
arin with normal saline for the prevention of occlusion of CVCs
were considered for this review. Due to potential bias, we excluded
studies that used alternative methods (quasi-randomised) to allo-
cate participants to a control or intervention group.
Types of participants
The study population of interest comprised infants and children
aged 0 to 18 years of age, who had a CVC (tunnelled catheter or
totally implanted catheter), inserted for long term venous access.
Because midline catheters are not placed in the same position as
a CVC (superior or inferior vena cava), and PICC have narrow
lumens which require specific care, studies of infants or children
with midline catheters or PICCs were beyond the scope of this
review and were excluded. There were no restrictions on the in-
sertion site, or catheter tip placement site (superior or inferior
vena cava). There were no restrictions on the healthcare setting in
which the study was conducted, for example tertiary hospital or
community setting. Where studies had a mixed population that
included infants, children and adults, we included data from in-
fants and children only. If information was not presented in the
article, we contacted the study authors to attempt to obtain age-
stratified results. If we were unable to contact the study authors,
and children and infants comprised a proportion greater than 20%
of the study population, we included the appropriate proportion
of participants to represent the paediatric component. If we were
unable to obtain any information regarding the proportion of in-
fants and children in the study population, we excluded the study
from the review.
Types of interventions
The intervention of interest was the intermittent (any time fre-
quency) flushing of heparin (any dose or concentration) compared
with intermittent flushing with normal saline (alone, or in com-
bination with pulsatile flushing techniques, positive displacement
devices or positive pressure lock) delivered with the intention to
prevent occlusion of the CVC.
Types of outcome measures
Outcomemeasureswere not considered a part of eligibility criteria.
Primary outcomes
• Occlusion of the CVC, determined by the inability to
infuse fluids through the catheter.
• CVC-associated blood stream infection or colonisation of
the catheter.
• Duration in days of catheter placement.
Secondary outcomes
• Inability to withdraw blood from the CVC.
• Any use of urokinase or recombinant tissue plasminogen
such as alteplase.
• Incidence of removal/re-insertion of the catheter.
• Other CVC-related complication (e.g. dislocation of CVCs,
thrombosis, tunnel or site infection, allergic reaction,
haemorrhage, heparin-induced thrombocytopaenia, elevated
hepatic enzymes.
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Search methods for identification of studies
No restrictions were placed on language.
Electronic searches
The Cochrane Vascular Trials Search Co-ordinator (TSC)
searched the Specialised Register (last searched April 2015) and
theCochrane Register of Studies (CRS) http://www.metaxis.com/
CRSWeb/Index.asp (2015, Issue 3). See Appendix 1 for details of
the search strategy used to search the CRS. The Specialised Reg-
ister is maintained by the TSC and is constructed from weekly
electronic searches of MEDLINE, EMBASE, CINAHL, AMED,
and through handsearching relevant journals. The full list of the
databases, journals and conference proceedings which have been
searched, as well as the search strategies used are described in the
Specialised Register section of the Cochrane Vascular module in
the Cochrane Library (www.cochranelibrary.com).
The following trial databases were searched by the TSC in April
2015 for details of ongoing and unpublished studies using the
terms heparin and sodium and (catheter or cannula or CVC or
PICC):
• World Health Organization International Clinical Trials
Registry http://apps.who.int/trialsearch/
• ClinicalTrials.gov http://clinicaltrials.gov/
• Current Controlled Trials http://www.controlled-
trials.com/
Searching other resources
Two review authors (NB, RE) screened the reference lists of re-
trieved articles for additional studies. We attempted to contact au-
thors of any studies identified in unpublished literature to obtain
further data.
Data collection and analysis
Selection of studies
Two review authors (NB, RE) independently reviewed all titles
and abstracts of retrieved articles to assess eligibility against inclu-
sion criteria. Where disagreement existed regarding the inclusion
of a study, the third author (RC) was consulted. We obtained the
full text of all potentially eligible studies and contacted authors
of primary studies to clarify data if necessary. A flowchart based
upon the Preferred Reported Items for Systematic Reviews and
Meta-Analysis (PRISMA) (Moher 2009) statement was used to
document results. We recorded data on the results of all searches
undertaken including: database searched; date; limiters, and num-
ber of results.
Data extraction and management
Two review authors (NB, RC) extracted the data independently
using the Cochrane Vascular Group forms for dichotomous and
continuous data. Data were collected regarding the:
• lead author and year of study;
• country where the study was undertaken;
• participant inclusion criteria;
• participant age and gender;
• study design;
• description of interventions;
• setting of study;
• number of participants in each arm;
• attrition or losses to follow-up;
• outcome measures.
We resolved any disagreement regarding data extraction by discus-
sion between all review authors (NB, RE, RC).
Assessment of risk of bias in included studies
We assessed bias within studies using the tool described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011a) and report the following domains: sequence generation;
allocation concealment; blinding; incomplete data; selective out-
come reporting, and other biases. If necessary, primary authors
were contacted to clarify any information. Two review authors
(NB, RC) independently undertook the risk of bias assessment.
Disagreement regarding the assessment of bias was resolved by dis-
cussion between review authors (NB, RC).
Measures of treatment effect
As dichotomous outcomes such as occlusion or central line-as-
sociated blood stream infection could occur more than once for
individual participants, we calculated count data per time at risk
of outcome (per 1000 catheter days) and reported rate ratios with
95%confidence intervals (CI). Using section 9.4.8 of theCochrane
Handbook for Systematic Reviews of Interventions (Deeks 2011), we
also calculated the formula for the log of the standard error for each
rate ratio. Descriptive statistics including mean differences (MD)
with 95% CI were used for any continuous data. We planned to
report time-to-event data as hazard ratios (HR) with 95% CI. We
analysed data with Review Manager software (RevMan) (RevMan
2014).
Unit of analysis issues
We identified the unit of analysis for each trial for intervention
(normal saline) and control (heparin) groups. Where results were
reported from cluster randomised controlled trials, cross-over tri-
als or repeated measurements of the same outcome, we took the
appropriate design effect into consideration to avoid unit of anal-
ysis error.
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Dealing with missing data
We contacted primary authors of studies to attempt to obtain any
missing data. We assessed all data for potential mislabelling and
made no assumptions regarding missing data in order to include
these in the analysis. Where data were missing and not able to be
obtained, we excluded them from the analysis.
Assessment of heterogeneity
Where feasible, we assessed heterogeneity between effect sizes of
included studies by visual inspection of forest plots and the Chi
2 test (P value < 0.05). We planned to describe inconsistency be-
tween trials by assessing the I2 statistic and the variability between
the effect estimates (Higgins 2003), with an I2 value of 50% con-
sidered to represent substantial heterogeneity (Higgins 2011). Ad-
ditionally we considered the clinical heterogeneity of studies where
the frequency of interventions, or catheter type differed between
studies.
Assessment of reporting biases
Where appropriate, we planned to assess publication bias using
funnel plots and Egger’s tests (Egger 1997; Sterne 2011). Addi-
tionally, we reduced reporting bias by searchingmultiple electronic
databases, proceedings of conferences and scientific meetings, and
trial registries. We excluded duplicates of the same trial to avoid
duplicate publication bias.
Data synthesis
The primary author (NB) entered data into RevMan (RevMan
2014) and undertook analysis according to recommended guide-
lines (Deeks 2011). We planned to combine effect sizes across
studies using a fixed-effectmodel and confidence interval limits set
at 95%. Where substantial heterogeneity existed, we pooled data
using the random-effects model. Where it was not appropriate
to combine results, we presented a narrative review descriptively
summarising the results.
Subgroup analysis and investigation of heterogeneity
Weplanned to conduct subgroup analysis where appropriate with:
type of CVC (tunnelled catheter or implanted port); insertion site
or catheter tip placement site, or both; age group; and diagnosis.
Sensitivity analysis
Weplanned to undertake sensitivity analyses to examine the effects
of different trials and their methodology including; number of
participants (greater than 50 versus fewer than 50 participants);
and duration of follow up.
Summary of findings
We presented the main findings of the review results concerning
the quality of evidence, the magnitude of effect of the interven-
tions examined, and the sum of available data for the primary out-
comes CVC occlusion rate and CVC-associated blood stream in-
fection in Summary of findings for the main comparison, accord-
ing to Schünemann 2011 and Atkins 2004. The GRADEprofiler
(GRADEpro) software was used to assist in the preparation of the
’Summary of findings’ table (GRADEpro GDT 2015).
R E S U L T S
Description of studies
See Figure 1; Characteristics of included studies; Characteristics
of excluded studies
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Figure 1. Study flow diagram.
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Results of the search
See Figure 1.
We contacted three individual study authors for further study de-
tails (De Neef 2002; Goossens 2013; Smith 1991) but we were
unable to obtain further information regarding the Smith 1991 or
De Neef 2002 studies. The authors of Goossens 2013 provided
data for paediatric patients.
Included studies
Based on the review of full texts, three studies met eligibility crite-
ria and were included in the final review (Cesaro 2009; Goossens
2013; Smith 1991) (see Table: Characteristics of included studies).
The studies undertaken by Cesaro 2009 and Goossens 2013 were
ofmediumduration (25 and 23months respectively) and included
a follow up periods of 14 and six months respectively. The Smith
1991 study was a cross-over study of two, three-and-a-half month
time periods (total duration seven months) and did not include a
follow-up period. We were not able to ascertain if this study was
analysed as paired data or not, and no information was available
regarding the first cross-over period. All studies had obtained eth-
ical approval from their relevant institutions.
Population
The three included trials involved a total of 245 participants, with
themajority of participants (203) coming fromCesaro 2009. From
the other two studies, Goossens 2013 contributed 28 participants,
and Smith 1991 contributed 14 participants. All participants had
a long-term central venous catheter placed, and were undergoing
treatment for haematology or oncology conditions. Cesaro 2009
was undertaken in Italy, Goossens 2013 in Belgium, and Smith
1991 in Canada. Participants in Smith 1991 and Cesaro 2009
had Broviac tunnelled CVCs inserted, whereas all participants in
Goossens 2013 had totally inserted catheters (ports) placed. All
studies were undertaken in developed nations in tertiary referral
centres. Both Cesaro 2009 and Goossens 2013 undertook power
size calculations to obtain sample sizes, however it is important
to note that children comprised only 3.5% of the Goossens 2013
study population, thus this study was not powered to analyse the
results of children separately.
Intervention
Participants in all three included studies received standard care
except where stated as follows. All included studies involved an
experimental arm where normal saline solution was used in place
of standard solution (heparinised saline) when the CVC was not
being used. As well as changing the type of solution used to flush
the CVC, Smith 1991 increased the duration between flushes in
the intervention arm. Participants in the standard arm received
standard care with CVCs flushed twice daily. In the intervention
arm, the duration between flushes was increased to weekly. Sim-
ilarly, Cesaro 2009 increased the duration between flushes in the
intervention arm compared to standard care from twice per week
to weekly. Cesaro 2009 also introduced a positive pressure cap
into the intervention arm. These changes confound the interven-
tions so it is not possible to associate outcomes with the use of
the solution alone. Goossens 2013 was the only study included
in this review where the only difference between the intervention
and standard arm was the use of normal saline (experimental) or
heparin (standard) solution to flush the CVC under positive pres-
sure.
Control
In all studies, participants randomised to the standard arm received
various concentrations of heparinised saline to flush their CVC.
Particpants in Smith 1991’s study received 5 mL of 10 units/mL
heparinised saline (i.e. 50 units of heparin) twice daily. Participants
in Cesaro 2009’s study received 3mL of 200 units/mL heparinised
saline (i.e. 600 units of heparin) twice weekly. In Goossens 2013’s
study, participants in the standard arm received maintenance care
(normal saline pulsatile flushes after infusions, blood sampling
etc), and their CVC was flushed with 3 mL of 100 units/mL
heparin (i.e. 300 units of heparin) under positive pressure at least
every eight weeks when the CVC was not in use.
Outcomes
The primary outcome of interest, occlusion of CVC, was mea-
sured in all three studies included in this review. In Smith 1991,
occlusion was defined as blockage of the catheter and measured by
both echocardiogram to determine thrombus formation and in-
ability to infuse fluids. Smith 1991 also recorded CVC-associated
blood stream and exit site infections. Blood stream infections were
defined by Smith 1991 as the presence of systemic infection and
positive blood cultures, and exit site infections were defined as the
presence of infection and positive culture from the exit site. Cesaro
2009 defined CVC occlusion as the inability to withdraw blood
or infuse fluids, or both. Cesaro 2009 also measured CVC-asso-
ciated blood stream infection, CVC mechanical issues and CVC-
related thrombosis. CVC-associated blood stream infection was
defined by Cesaro 2009 as one or more positive blood cultures ob-
tained through the CVC in patients with signs of infection. CVC
mechanical issues included dislodgement of the CVC tip or cuff,
fracture or accidental CVC self-removal by the patient; these out-
comes were evaluated by visual inspection and chest X-ray. CVC-
related thrombosis was measured where clinically indicated by ul-
trasound, computed tomography or magnetic resonance imaging.
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Goossens 2013measuredCVCocclusion as a secondary endpoint,
their primary outcome was partial occlusion defined by easy infu-
sion, difficulty withdrawing fromCVC.Other secondary outcome
measures in Goossens 2013 wereCVC-associated blood stream in-
fection and other CVC mechanical issues. CVC-associated blood
stream infection was defined by Goossens 2013 as positive blood
cultures from the CVC and peripheral veins, and fever or chills
in the absence of other infection sources. CVC mechanical issues
encompassed all other functional problems encountered with each
access. As participants could experience outcomesmore than once,
all studies reported the number of catheter days that participants
in either study arm were at risk of experiencing an outcome.
Excluded studies
Six studies were excluded from the review. None of the six ex-
cluded studies met eligibility criteria; Geritz 1992 and Schultz
2002 reported trials investigating peripheral catheters, De Neef
2002 and Kaneko 2004 studies investigated arterial catheters, and
Pumarola 2007 and Rabe 2002 investigated temporary central ve-
nous catheters. Additionally , Kaneko 2004 and Rabe 2002 did
not include children in their study population. See: Characteristics
of excluded studies.
Risk of bias in included studies
See risk of bias: Figure 2 and Figure 3 and also Characteristics of
included studies.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
There was low risk of selection bias in the Cesaro 2009 and
Goossens 2013 studies; these investigators reported using com-
puterised random sequencing and concealing allocation until par-
ticipants had been recruited and provided consent. Smith 1991’s
study did not provide any details regarding how participants were
randomised and was therefore judged to be of unclear risk of se-
lection bias.
Blinding
None of the three included studies blinded investigators, clinicians
or participants regarding to which arm the participant had been
allocated. Goossens 2013 stated blinding was not possible for lo-
gistical reasons. All outcomes were objectively measured, but in all
three studies there is the possibility clinicians may have modified
their technique depending on the arm to which the participant
had been allocated. All studies were therefore assessed as a high
risk of both performance and detection bias.
Incomplete outcome data
All three studies included in this review reported full results for
all participants who were randomised. A flow chart of participant
progress through the study was provided byGoossens 2013. There
were no protocol violations reported by Goossens 2013 or Cesaro
2009. In Goossens 2013 there was a 4.9%drop-out rate which was
not statistically different between the two groups and all analysis
was based on intention-to-treat. This drop out rate relates to the
adult participants and not the children included in this review. In
Cesaro 2009 22% (n = 44) of CVCs required premature removal,
however there were no statistical differences between study arms.
Attrition of two participants due to death also occurred in this
study but no losses to follow up occurred. Smith 1991 reported no
losses to follow up. Cesaro 2009 andGoossens 2013 were assigned
a low risk of attrition bias, and Smith 1991 an unclear risk.
Selective reporting
All studies reported on their primary and secondary outcomemea-
sures. There were no study protocols available for any studies,
therefore reporting bias for all studies is unclear. Smith 1991 re-
ported data in a basic format with no results from statistical tests.
It is not clear if paired analysis was undertaken; this study was
assessed at being at high risk for reporting bias.
Other potential sources of bias
In both the Cesaro 2009 and Smith 1991 studies, there is a high
concern for confounding of results. Both these studies altered the
frequency between flushes for the experimental arm as well as the
experimental solution. Additionally in Cesaro 2009 the experi-
mental arm included the use of a positive pressure cap. It is not
possible therefore to attribute the outcome to the use of the solu-
tion alone, the outcome could plausibly also be attributed to the
frequency of flushes or the use of a positive pressure cap. It may
therefore be more appropriate to view the intervention as a com-
ponent of a bundle of care. Further bias may exist in the subset of
unpublished data of paediatric participants provided by Goossens
2013; we were not able to determine if the characteristics of this
subset of participants were subject to other biases. As a cross over
study there may have been a carry-over effect of the intervention
from one arm to the other in Smith 1991. It is not clear if the
study authors considered this. These other potential sources of
bias across all three studies are substantial and reduce confidence
in the results.
Effects of interventions
See: Summary of findings for the main comparison Heparin
versus normal saline flushing for prevention of occlusion in long
term central venous catheters in infants and children
See: Summary of findings for themain comparison for the two pri-
mary outcomes CVC occlusion and CVC-associated blood stream
infection or colonisation. See Additional Table 1 for summary of
outcome rates per 1000 catheter days.
As we were not able to ascertain if Smith 1991 analysed data as
paired data or not, and no information was available regarding the
first cross-over period, the results from this study were not pooled
with the other studies..
Primary outcomes
Comparison: normal saline versus heparin
CVC occlusion (Analysis 1.1)
CVC occlusion was reported in all three included trials (243 par-
ticipants; Goossens 2013 provided data for 26 of 28 participants
for CVC occlusion). Smith 1991 and Cesaro 2009 provided in-
formation regarding the number of catheter days for each arm
of their study. Goossens 2013 provided the mean catheter days
for each arm of the total population in their study (i.e. includ-
ing both the child and adult participants). We assumed that the
mean number of catheter days for the child participants in each
study arm was comparable to that of the adult participants. Based
on this information, we calculated the occlusion rate ratio for the
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experimental arm (normal saline) versus the standard arm (hep-
arin) for each study per 1000 catheter days. In both Smith 1991
and Cesaro 2009 there were more CVC occlusions in the exper-
imental (normal saline) arm. The rate ratio of CVC occlusion in
Smith 1991 was 2.0 (95% CI 0.18 to 21.85), and in Cesaro 2009
the rate ratio was 1.95 (95% CI 1.34 to 2.83). Goossens 2013
found there were fewer CVC occlusions in the experimental (nor-
mal saline) arm; the rate ratio was 0.25 (95% CI 0.09 to 0.73).
Because of absent data regarding the first period in the cross-over
study design used in Smith 1991, results from this study were not
pooled. When the results from the Cesaro 2009 and Goossens
2013 studies were pooled, the heterogeneity was 92% (I2 = 92%);
the random-effects model was chosen to estimate the combined
effect. While combined analysis suggested there was no statisti-
cal difference in the outcome of CVC occlusion between flushing
with heparin or normal saline (rate ratio 0.75, 95% CI 0.10 to
5.51; participants = 229; studies = 2; Z = 0.29, P = 0.78), the
heterogeneity between studies indicates this result may be due to
differences between the studies. See Analysis 1.1 and Figure 4. We
graded this evidence as very low quality (see Summary of findings
for the main comparison).
Figure 4. Forest plot of comparison: 1 Comparison: Normal saline versus heparin flush, outcome: 1.1
Outcome 1: CVC occlusion rate per 1000 catheter days.
CVC-associated blood stream infection or colonisation
(Analysis 1.2)
Incidence of CVC-associated blood stream infection was reported
in all three included trials (245 participants). As described above,
rate ratios were calculated for each study based upon 1000 catheter
days. There were more CVC-associated blood stream infections
in the experimental (normal saline) arm in both Smith 1991 and
Cesaro 2009 studies. The rate ratio in Smith 1991 was 2.00 (95%
CI 0.18 to 21.85); in Cesaro 2009 the rate ratio was 2.58 (95%
CI 1.20 to 5.54). In Goossens 2013, there were no incidences
of infection in the experimental (normal saline) arm, therefore
in order to calculate the log of the standard error for the rate
ratio, as per section 9.4.8 of the Cochrane Handbook for Systematic
Reviews of Interventions , 0.5 was added to each arm of the study
(Deeks 2011). The resulting calculation in Goossens 2013 was a
rate ratio of 0.30 (95% CI 0.01 to 6.26). We pooled the results
of Cesaro 2009 and Goossens 2013. The heterogeneity between
studies was 45% (I2 = 45). Because the I2 statistic approached
50% and there was also evidence of clinical heterogeneity between
the studies, (e.g. difference in frequency of flushing, implanted
catheters and tunnelled catheters, use of positive pressure cap) the
random-effects model was used. See Analysis 1.2 and Figure 5.
There is no significant association between the use of saline to flush
CVC and the incidence of CVCassociated blood stream infection
(rate ratio 1.48, 95% CI 0.24 to 9.37; participants = 231; studies
= 2; Z = 0.42, P = 0.67). We graded this evidence as low quality
(see Summary of findings for the main comparison).
Figure 5. Forest plot of comparison: 1 Comparison: Normal saline versus heparin flush, outcome: 1.2
Outcome 2: CVC-associated blood stream infection rate per 1000 catheter days.
14Heparin versus 0.9% sodium chloride intermittent flushing for the prevention of occlusion in long term central venous catheters in
infants and children (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Duration of CVC placement (days)
After a median follow-up of 360 days, Cesaro 2009 reported that
CVC survival was similar between the two study arms (203 par-
ticipants). In the experimental (normal saline) arm mean survival
was reported as 77% (95% CI 66% to 84%), and in the standard
(heparin) arm mean survival was reported as 69% (95% CI 53%
to 80%).
Duration of CVC placement was not reported in either Goossens
2013 or Smith 1991.
Secondary outcomes
Inability to withdraw blood from the CVC
Goossens 2013 reported on the inability to withdraw blood from
the CVC (26 participants). Compared to the experimental (nor-
mal saline) group, there was a decreased inability to withdraw
blood from the CVC in the heparin group, rate ratio 0.32 (95%
CI 0.14 to 0.88). Cesaro 2009 and Smith 1991 did not report on
the (in)ability to withdraw blood from the CVC.
Any use of urokinase or recombinant tissue plasminogen
Urokinase was used in 116 of 124 (94%) episodes of CVC oc-
clusion in the Cesaro 2009 study of 203 patients, and patency
was restored in 107 out of 116 (92%). No specific information
was available regarding which treatment arm urokinase was used
in and the subsequent result, however it is noted that 83 CVCs
occluded in the normal saline group and 41 in the heparin group.
Five of the CVCs were occluded in only one lumen and so were
left in situ while the remaining four were unable to have patency
restored in either lumen and were prematurely removed. There
was no information available regarding the use of urokinase or
other drugs to restore patency in either Goossens 2013 or Smith
1991.
Incidence of removal/re-insertion of the catheter
Cesaro 2009 reported premature removal of aCVCwas required in
44 participants, 22% of the total study population of 203 patients.
Premature removal was comparable between the two study arms,
21 in the saline arm and 23 in the heparin arm, and was generally
indicated because of dislocation of the catheter or infection, rather
than CVC occlusion. There was no information regarding this
outcome from Goossens 2013 or Smith 1991.
Other CVC-related complications
Dislodgment of the CVC occurred in 38/203 (19%) of the total
study population in Cesaro 2009. There were no statistical differ-
ences between study arms; rate ratio 0.87 (95% CI 0.46 to 1.63).
In Smith 1991, dislodgement occurred in 2/14 (14%) of the study
population. There was no statistically significant difference be-
tween study arms; rate ratio 0.2 (95%CI 0.01 to 4.81). There was
no information regarding this outcome available from Goossens
2013.
CVC site infection was reported in 24/203 (12%) in Cesaro 2009
with no statistically significant differences between study arms;
rate ratio 0.68 (95% CI 0.30 to 1.52). In Smith 1991 CVC site
infection was reported in 6/28 (21%) of the study population,
again there was no difference between study arms; rate ratio 7.0
(95% CI 0.37 to 132.4).
CVC-related thrombosis was reported in 2/203 (1%) of the study
population in Cesaro 2009 with no differences between study
arms; rate ratio 1.0 (95%CI 0.06 to 15.86). In Smith 1991, CVC-
related thrombosis was reported in 2/14 (14%) of the population,
again there was no difference between study arms; rate ratio 1.0
(95% CI 0.06 to 15.86).
There were no data available from Goossens 2013 regarding other
CVC complications in the paediatric population of 28 patients.
Subgroup analysis
As there were only three studies included in this review, we were
not able to undertake any subgroup analysis.
Sensitivity analysis
Due to the limited number of studies in this review, it was not
appropriate to undertake a sensitivity analysis.
D I S C U S S I O N
Summary of main results
This systematic review compared the use of heparin locks (stan-
dard care) with experimental use of 0.9% sodium chloride (nor-
mal saline) locks. The outcomes of interest were: CVC occlu-
sion; CVC-associated blood stream infection; duration in days of
catheter placement, inability to withdraw blood from the CVC;
use of urokinase or recombinant tissue plasminogen; incidence of
removal or re-insertion of the CVC, or both; dislocation of the
CVC; other CVC infection; thrombosis associated with CVC; al-
lergic reaction; haemorrhage; heparin-induced thrombocytopae-
nia, and elevated hepatic enzymes. Rate ratios were calculated for
outcome measures to estimate the probability of each event occur-
ring in each treatment arm. See Summary of findings for the main
comparison for details on the primary outcomes CVC occlusion
and CVC-associated blood stream infection. The quantity of the
evidence was small; we were only able to include three studies and
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the results were inconsistent. We found that there is insufficient
data to determine the effects of intermittent flushing of normal
saline verus heparin to prevent CVC occlusion or CVC-associated
blood stream infection in infants and children. The use of a pos-
itive pressure cap in Cesaro 2009 may have biased the results of
this study regarding the outcome of CVC-associated blood stream
infection; there is evidence of an association between the use of a
positive pressure cap and CVC-associated blood stream infection
in other studies (Jacobs 2004; Jarvis 2009; Marschall 2008). The
quality and strength of the evidence for the use of normal saline
instead of heparin for the routine management of CVC is low and
further well designed studies are required.
Overall completeness and applicability of
evidence
The trials included in the review directly compared the use of
normal saline and heparin in long term central venous catheters
in children in community and acute settings, and we were able
to undertake two meta-analyses. All studies included participants
representative of those usually found in the clinical setting. How-
ever, between studies, all used different protocols for the standard
and experimental arms with different concentrations of heparin
and different frequency of flushes reported. Additionally, within
studies, Smith 1991 and Cesaro 2009 changed not only the solu-
tion being used, but also the frequency of flushes. Any difference
seen could therefore be plausibly attributed to either the solution
or the frequency of flushes; changing the frequency of flushes may
actually confound the results towards the null hypothesis.
The three included studies employed a pragmatic approach to as-
sess the effectiveness of saline in routine care. While this approach
is desirable to inform policy and routine practice, greater emphasis
is required to minimise bias and confounding in the study design
to ensure generalisibility. As there are concerns with the internal
validity of all three studies, the generalisibility (external validity)
of results from the studies included in the review is poor.
Quality of the evidence
Study methodology
The assessment of bias for all studies was summarised using
Cochrane’s risk of bias tool (Figure 3) and indicated a high level of
heterogeneity. There were methodological weaknesses in all stud-
ies. Because of the nature of the outcomes, it was not possible to
blind participants or clinicians. However it could be argued that, if
the frequency of flushes had been kept consistent between the ex-
perimental and standard arms, greater care could have been taken
to blind the intervention from both participants and clinicians.
Other concerns included the potential for selection bias, selective
reporting bias and possible confounding of results.
The study undertaken by Smith 1991 in particular is subject to
high levels of uncertainty regarding its precision. This study was
undertaken many years ago and is reported with minimal detail. It
is unclear how the datawere analysed (i.e. paired or un-paired), or if
individual participants experienced more than one outcome. Fol-
lowing this study, the institution where the study was conducted
changed their practice, replacing heparin with normal saline locks.
Recent communication with this institution (HHSC 2014 [pers
comm]) confirmed that the facility continues to routinely use nor-
mal saline locks for long term CVCs in children over 12 months
of age, providing strong support of the study’s findings. Therefore
despite the bias evident in this study, it is important to consider
the clinical implications of the experience of the efficacy of normal
saline locks in long term CVCs over two decades.
In the study reported by Cesaro 2009, the randomisation process
is well reported and the study is methodologically sound. How-
ever there are concerns regarding the potential for outcomes to be
attributed to the positive pressure cap, or the frequency of flushes
(or a combination of both) and so it is unclear what role the flush-
ing solution plays.
Goossens 2013 did not intend for the subset of paediatric data
to be analysed separately; their study included a large number of
adults and only a small proportion of children (28/802, 3.5%).
As a consequence, not all the information required to make an
assessment of the quality of the study was available.
Heterogeneity, inconsistency and imprecision of
results
Whenwe combined the two studies (Cesaro 2009;Goossens 2013)
to assess the effect of normal saline on CVC occlusion, the hetero-
geneity was high. The combined results of both CVC occlusion
and CVC-associated blood stream infection revealed wide confi-
dence intervals (Analysis 1.1; Analysis 1.2 ) which included the
null hypothesis. The studies do not appear to provide consistent
information and we were unable to determine the precision of
the studies. The small sample sizes and the few events in the two
studies are likely the cause of this heterogeneity.
The overall quality of the evidence was assessed as very low to low
using the GRADE assessment tool; there was a high risk of perfor-
mance and detection bias in all studies as well as a high risk of other
bias related to differences in frequency of flushes between heparin
and saline groups in Cesaro 2009 and Smith 1991. A high risk of
other bias is also assumed for the subset of unpublished paediatric
data provided for Goossens 2013. In addition we identified het-
erogeneity, imprecision and inconsistency of the effect estimates.
Consequently, the significance of the results of thesemeta-analyses
should be interpreted with caution. Further research is likely to
improve the confidence in the estimate of these effects if under-
taken with greater attention to methodology.
Potential biases in the review process
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None of the review authors were investigators in any of the studies
included in this review. The literature review was thorough and
the methodology transparent and can be reproduced. None of the
review authors had any conflicts of interest to declare. While we
attempted tominimise bias in this review as described above, we are
aware that there are differing practices worldwide and there may
be unpublished studies which were not included in this review.
The review authors made assumptions with the paediatric data
provided in the Goossens 2013 study that the subset of paediatric
patients had the same catheter days at risk as reported in the larger
study; these assumptions may have introduced bias in the review
process. We originally defined the study population as children
and infants aged 1-18 years. The included studies had recruited
children from aged 0 - 20 years, accordingly we changed our study
population to include these ages as there was not enough data
available to exclude children aged under 1 year in Cesaro 2009 or
over 18 years in Smith 1991; we made the assumption this was
unlikely to effect the results.
Agreements and disagreements with other
studies or reviews
A recent systematic review (Conway 2014) concurred with our
findings that there is insufficient evidence to support the use of nor-
mal saline to prevent CVC occlusion. This review included stud-
ies related to the adult population and also peripherally inserted
CVCs. Conway 2014 concluded with recommendations for daily
flushing with heparin based on the practices of selected facilities.
However, there is insufficient evidence to make this recommen-
dation and this recommendation may lead to higher amounts of
heparin being used than is necessary, introducing avoidable costs
and risks associated with the use of heparin in this patient group.
Peripherally inserted CVCs have a much narrower lumen and re-
quire different care and thus were excluded from this Cochrane
Review.
There are numerous observational studies that investigate this issue
(Bowers 2008; Fratino 2005). Many of these studies support the
use of normal saline for routine flushing of long termCVCs (Abate
2013; Kelly 2008) and institutions report the practice of using
normal saline in their clinical practice guidelines (Nelson 2008).
Despite the literature suggesting that heparin may not be required
to maintain patency of CVCs, more RCTs are required to deter-
mine the ideal flush solution, concentration, and the frequency of
flushes (Baskin 2009).Without strong evidence to support the use
normal saline, debate will continue and inconsistencies in practice
will prevail. In an area where patients are already vulnerable as a
result of their disease state, there should be greater understanding
of this relatively simple question and practice should be standard-
ised.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient evidence to determine the effects of intermit-
tent flushing of heparin versus normal saline to prevent occlusion
in long term central venous catheters in infants and children. It
remains unclear whether heparin is necessary to prevent occlusion
or CVC-associated blood stream infection. Controversy between
institutions around the world regarding the appropriate care and
maintenance of these devices remains.
Implications for research
Given the results of this review, there is a need for healthcare or-
ganisations to consider undertaking further research in this area
to contribute to the evidence base. Ultimately this would facil-
itate the development of evidence-based clinical practice guide-
lines and consistency of practice. Careful attention to study de-
sign is required, including blinding and proper sample size calcu-
lations to detect clinically meaningful differences, and ensuring
only one aspect of the intervention is changed in the experimen-
tal arm (flushing frequency, concentration of heparin or use of
normal saline). Such studies would generate evidence and ensure
results could be appraised and generalised to address the current
gaps in knowledge. Consistency of outcome reporting would aid
interpretation of results. No studies measured the costs associated
with standard or experimental treatment; cost analysis would be
a useful addition to future studies. Alternatively, decision models
could be used to ascertain what differences in complication rates
would make a meaningful difference in costs or outcomes.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Cesaro 2009
Methods Studydesign:prospective parallel randomised controlled study, at a single tertiary referral
centre, during a 25-month study period
Method of randomisation: computer generated
Allocation of concealment: sealed envelopes
Participants Country: Italy
Setting: single tertiary referral centre
Numbers: 203 paediatric haematology or oncology patients with tunnelled Broviac
CVC. 101 participants randomised to experimental treatment and 102 participants
randomised to standard treatment group
Age: 0 to 17 years, age < 5 years = 39, age > 5 years = 62 in experimental group; age < 5
years = 41, age > 5 years = 61 in standard treatment group
Gender: 60 male, 41 female in experimental group; 60 male, 42 female in standard
treatment group
Catheter days at risk:tTotal of 75,249 catheter days. Mean of 381 days per person
(range 11 to 1072) in the experimental group; 351 days per person (range 4 to 1073) in
the standard treatment group
Inclusion criteria: paediatric patient (0 to 17 years of age, with malignant or non-
malignant haematologic or oncologic disease with a Broviac-Hickman-type CVC- i.e.
tunnelled, partially inserted, open-ended, inserted for the purpose of chemotherapy of
haematopoietic stem cell transplantation
Exclusion criteria: not stated
Interventions Experimental treatment group:flushing with normal saline at least weekly via a positive
pressure cap
Standard treatment group: flushing with 3 mL of normal saline with 200 units heparin
twice weekly via a standard CVC cap
Outcomes • Incidence of CVC complications: occlusion, dislocation of CVC, CVC-related
infection, exit site infection, thrombosis
• CVC survival (weeks)
• Organisms isolated from blood cultures
Notes Potential confounding of results due to outcomes being attributable to positive pressure
cap or frequency between flushes rather than the flushing solution used
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Computer generated randomisa-
tion lists were drawnup by a statistician not
involved in patient management”
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Cesaro 2009 (Continued)
Allocation concealment (selection bias) Low risk Quote: “Stored by sequentially numbered
sealed envelopes. Permuted blocks of four
were used for treatment allocation. In-
formation concealed to investigators until
completion of recruitment”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no blinding of participants or
personnel. Different caps were used in the
different arms of the study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: due to nature of outcomes, not
possible to blind assessment of outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: low attrition rate, follow up for
median of 360 days, results from all en-
rolled participants were reported
Selective reporting (reporting bias) Unclear risk Comment: all nominated outcome data
were reported. No study protocol available
Other bias High risk Comment: outcomes could also be at-
tributed to different caps, or frequency of
flushing, not only to use of different solu-
tions
Goossens 2013
Methods Study design: prospective parallel randomised controlled trial, at a single tertiary referral
centre, during a 23-month study period
Method of randomisation: computer generated
Allocation of concealment: sequentially numbered cards located in a separate area
Participants Country: Belgium
Setting: single tertiary referral centre
Numbers: 802 individuals with an oncology or haematology condition, who had a
totally implantable intravenous catheter inserted. A subset of unpublished data was
obtained from the investigators for 28 (3.5%) participants, aged one to 18 years of age; 11
participants were randomised to experimental treatment group and 17 were randomised
to standard treatment group. No further details available for paediatric subset of data
Age: 1 - 71 years, mean age 57.9 years (SD 14.8) in experimental group; mean age 54.
9 years (SD 16.6) in standard treatment arm. Further details not available for paediatric
subset
Gender: 261 (64.6%) female in experimental group, 263 (66.1%) female in standard
treatment groups. Further details not available paediatric subset
Catheter days at risk: total catheter days 115,991: 58,197 in the experimental treatment
arm (mean 152.4 days per patient); 57,794 in the standard treatment arm (mean 150.9
days per patient). The assumption was made that the mean catheter days was equivalent
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Goossens 2013 (Continued)
in the paediatric population
Inclusion criteria: patients older that one year of age, scheduled for insertion of a totally
implantable central venous catheter for the first time, with a haematology or oncology
condition and expected to survive for the planned follow up of 180 days
Exclusion criteria: patients (or caregivers in the case of children) unable to provide
informed consent, unable to stand for a post-operative chest X-ray, patients with thera-
peutic intravenous heparin administration, a history of HIT or abnormal clotting tests,
or coincident participation in other clinical trials
Interventions Experimental treatment group: pulsatile flushing with 10 mL of normal saline and
then locking with positive pressure
Standard treatment group: pulsatile flushing with 10 mL of normal saline, followed by
3 mL heparin (100 units/mL) and locking with positive pressure
Outcomes • Rate of inability to aspirate blood while injection was easy (assessed at every access)
• Incidence of CVC-associated blood stream infection
• Incidence of functional problems associated with CVC
Notes Subset of paediatric data (unpublished) was obtained to assess outcomes for children
only: 26 out of 28 children contributed data. Not all variables available, there may be
some systematic differences in the characteristics of children in the subset of data, the
study was not powered to analyse this subset of data separately
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “We randomly assigned patients
in a 1:1 ratio using computerised random
numbers to two groups”
Allocation concealment (selection bias) Low risk Quote: “The allocation sequence was con-
cealed from researchers who enrolled pa-
tients according to sequentially numbered
patient cards stored in a separate room.”
Patients were assigned to groups following
providing consent to participate
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no blinding of participants or
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: due to nature of outcomes, it
was not possible to blind the assessment of
outcomes
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: attrition occurred with adult
participants, however analysis was based on
CVC access rate rather than individual pa-
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Goossens 2013 (Continued)
tient data. Unsure if paediatric data was
complete
Selective reporting (reporting bias) Unclear risk Comment: all nominated outcome data
were reported. No study protocol available
Other bias High risk Comment: subset of paediatric data was
unpublished, provided by the study author;
there may be systematic differences of par-
ticipant characteristics in this subset of data
Smith 1991
Methods Study design: prospective cross-over randomised controlled trial, at a single tertiary
referral centre, during a seven month study period
Method of randomisation: no information available
Allocation of concealment: no information available
Participants Country: Canada
Setting: single tertiary referral centre
Numbers: 14 participants with tunnelled Broviac CVC
Age: 21 months to 20 years of age (median 5.4). As a cross-over design, the same
participants were in both the experimental treatment group and the standard treatment
group
Gender: no information available
Mean duration of catheter days at risk: total catheter days 3029: 1515 catheter days
(mean 108 days per person) in experimental arm and 1514 (mean 108 days per person)
in the standard arm
Incusion criteria: none stated. All patients had CVCs placed prior to entering study
Exculsion criteria: none stated
Interventions Experimental treatment group: once per week flush with 9 mL normal saline
Standard treatment group: twice daily flushes with 5 mL heparinised normal saline (10
units/mL heparin)
Outcomes • Thrombosis formation at baseline, cross over point (14 weeks) and end of study
(28 weeks) as measured by echocardiogram or inability to infuse or withdraw from
CVC (occlusion)
• Incidence of CVC mechanical issues (leak, migration)
• Incidence of CVC-associated infection
Notes Older study, not reported using contemporary standards. Potential for confounding of
results due to outcomes being attributable to frequency between flushes rather than
solution used. No information available for first cross-over period results
Risk of bias
Bias Authors’ judgement Support for judgement
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Smith 1991 (Continued)
Random sequence generation (selection
bias)
Unclear risk Comment: no information provided re-
garding sequence generation for randomi-
sation; cross-over design but no informa-
tion regarding how participants were se-
lected
Quote: “patients were randomised to one
of two methods of catheter care and then
crossed over at the end of a three and a half
month period to the opposite arm for an
additional three and a half month period”
Allocation concealment (selection bias) Unclear risk Comment: no information provided re-
garding allocation concealment, however
as a cross-over design all participants were
their own controls
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Comment: no blinding of participants or
personnel
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: due to nature of outcomes, not
possible to blind assessment of outcomes
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: no attrition in study, results
from all enrolled participants reported
Selective reporting (reporting bias) High risk Comment: all nominated outcome data re-
ported in basic format, no results from sta-
tistical tests reported. It is not clear if paired
analysis was undertaken. No study proto-
col available
Other bias High risk Comment: unable to establish if authors
considered carry-over effect of the inter-
ventions from one arm to the other; pos-
sible selection bias. Outcomes could also
be attributed to alterations between the fre-
quency of flushes
CVC: central venous catheter
HIT: heparin-induced thrombocytopenia
SD: standard deviation
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
De Neef 2002 Type of catheter not relevant
Geritz 1992 Type of catheter not relevant
Kaneko 2004 Population not relevant - adults aged over 18 years
Pumarola 2007 Type of catheter not relevant
Rabe 2002 Type of catheter not relevant and population aged over 18 years
Schultz 2002 Type of catheter not relevant
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D A T A A N D A N A L Y S E S
Comparison 1. Heparin versus normal saline flushing
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 CVC occlusion rate per 1000
catheter days
2 229 Rate Ratio (Random, 95% CI) 0.75 [0.10, 5.51]
2 CVC-associated blood stream
infection rate per 1000 catheter
days
2 231 Rate Ratio (Random, 95% CI) 1.48 [0.24, 9.37]
A D D I T I O N A L T A B L E S
Table 1. Rate per 1000 catheter days for primary and secondary outcomes
Smith 1991 Cesaro 2009 Goossens 2013
Outcome Normal Saline Heparin Normal Saline Heparin Normal Saline Heparin
CVC occlusion
rate per 1000
catheter days
1.32 0.66 2.16 1.11 2.62 10.35
CVC-
associated blood
stream infection
rate per 1000
catheter days
1.32 0.66 0.62 0.24 0.32 1.04
Inability to with-
draw blood
Not reported Not reported Not reported Not reported 3.42 10.60
CVC dislodge-
ment
0.33 1.65 0.47 0.54 Not reported Not reported
CVC site infec-
tion
2.31 0.33 0.26 0.38 Not reported Not reported
CVC-related
thrombosis
0.66 0.66 0.30 0.30 Not reported Not reported
CVC: Central venous catheter
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The duration of catheter placement was changed from number of weeks in the protocol, to number of days in the review as per the
reported outcomes in the included studies’ reported outcomes.
A secondary outcome measure of dislocation of CVCs was included in the review as it was deemed an important clinical variable.
We originally planned to use odds ratios or risk ratios in the published protocol, however outcome measures were not reported
consistently in studies. As all included studies reported the number of catheter days for each study population, we were able to calculate
rate ratios as a common metric to compare and report outcomes.
We originally defined the study population as children and infants aged 1 to 18 years. The included studies had recruited children
from aged 0 to 20 years, accordingly we changed our study population to include these ages as there was not enough data available to
exclude children aged under one year in Cesaro 2009 or over 18 years in Smith 1991; we made the assumption this was unlikely to
effect the results.
We have included a ’Summary of findings’ table and GRADE assessment of the evidence according to current Cochrane guidelines.
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